XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

Detailed summary

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout ...

CALGARY, Alberta, Nov. 13, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that the Japan Patent Office (the “JPO”) has issued a Decision to Grant a Patent for Japanese Patent Application No. 2022-556140, entitled “Compositions, Formulations, and Containers” (the “Japanese Patent”).

A Decision to Grant is the JPO’s determination that the examiner has found no reasons to refuse the application. The Japanese Patent will issue upon payment of the registration fee and registration by the JPO. The application is the Japanese national phase of International Application No. PCT/IB2021/000238 and claims priority to U.S. Provisional Application No. 62/989,879, filed March 15, 2020. The six allowed claims are directed to pharmaceutical compositions comprising a xanthine oxidase inhibitor, including oxypurinol, for the treatment or prevention of acute kidney injury and other health consequences associated with viral infection.

“This decision is expected to provide XRx-101 with its first patent protection in Japan, one of the world’s largest pharmaceutical markets, and the allowed claims are directed to the central premise of the program – that inhibiting xanthine oxidase may attenuate injurious, rapid increases in uric acid and the acute kidney injury that can follow serious respiratory viral infection,” stated Dr.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections.

Opening of the article, excerpted from Toronto Star. To read the rest, open the article on the publisher's site.